Epics therapeutics
EPICS Therapeutics is a clinical-stage biotechnology company pioneering small-molecule modulators of RNA epigenetics for cancer treatment. The company focuses on the epitranscriptome, a process where specialized enzymes write, read, and erase marks on RNA that control how and when cells use genetic instructions. Its lead program, EP102, is a first-in-class potent and selective small-molecule inhibitor of METTL3, the…
Funding snapshot
About
EPICS Therapeutics is a clinical-stage biotechnology company pioneering small-molecule modulators of RNA epigenetics for cancer treatment. The company focuses on the epitranscriptome, a process where specialized enzymes write, read, and erase marks on RNA that control how and when cells use genetic instructions. Its lead program, EP102, is a first-in-class potent and selective small-molecule inhibitor of METTL3, the enzyme responsible for installing the m6A mark on RNA, now advancing in clinical evaluation with patients with solid tumors. The pipeline also includes EP601, a GPR84 target in active preclinical development, and EP282, an FFAR2 target ready to enter Phase II clinical development for autoimmune disease treatment through the microbiome-immune axis. EPICS prioritizes cancers where METTL3 dysregulation intersects with DNA damage response pathways, including NSCLC, pancreatic cancer, ovarian cancer, and colorectal cancer. Founded in 2018 and headquartered in Charleroi, Belgium, the company has raised $24.7M in Series A funding from investors including SRIW, BNP Paribas Fortis, Sambrinvest, Investsud, Theodorus, Fund+, SFPI, and Capitaletcroissance.be.
Business model
Oncology > Drugs > Pan Cancer,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.